



Corrigendum: Telmisartan Prevents Alveolar Bone Loss by Decreasing the Expression of Osteoclasts Markers in Hypertensive Rats With Periodontal Disease

Victor Gustavo Balera Brito^{1,2}, Mariana Sousa Patrocínio^{1,2}, Maria Carolina Linjardi^{1,2}, Ayná Emanuelli Alves Barreto^{1,2}, Sabrina CT Frasnelli^{1,2}, Vanessa Lara³, Carlos Ferreira Santos⁴ and Sandra Helena Penha Oliveira^{1,2*}

¹Department of Basic Sciences, School of Dentistry, São Paulo State University (UNESP), Araçatuba, Brazil, ²Multicenter Postgraduate Program in Physiological Sciences, Brazilian Society of Physiology, School of Dentistry, São Paulo State University (UNESP), Araçatuba, Brazil, ³Department of Stomatology, Bauru School of Dentistry, University of São Paulo, Bauru, Brazil, ⁴Department of Biological Science, Bauru School of Dentistry, University of São Paulo, Bauru, Brazil

OPEN ACCESS

Edited and reviewed by:

Ulrike Garscha,
University of Greifswald, Germany

*Correspondence:

Sandra Helena Penha Oliveira
sandra.hp.oliveira@unesp.br

Specialty section:

This article was submitted to
Inflammation Pharmacology,
a section of the journal
Frontiers in Pharmacology

Received: 30 November 2020

Accepted: 23 December 2020

Published: 19 February 2021

Citation:

Brito VGB, Patrocínio MS, Linjardi MC, Barreto AEA, Frasnelli SCT, Lara V, Santos CF and Oliveira SHP (2021) Corrigendum: Telmisartan Prevents Alveolar Bone Loss by Decreasing the Expression of Osteoclasts Markers in Hypertensive Rats With Periodontal Disease. *Front. Pharmacol.* 11:635927. doi: 10.3389/fphar.2020.635927

Keywords: telmisartan, AT1 blocker, bone metabolism, spontaneous hypertensive rats, periodontal disease, osteoblast, osteoclast, cytokines

A Corrigendum on

Telmisartan Prevents Alveolar Bone Loss by Decreasing the Expression of Osteoclasts Markers in Hypertensive Rats With Periodontal Disease

by Brito, V. G. B., Patrocínio, M. S., Linjardi, M. C., Barreto, A. E. A., Frasnelli, S. C. T., Lara, V., Santos, C. F., and Oliveira, S. H. P. *Front. Pharmacol.* 11:579926. doi: 10.3389/fphar.2020.579926

In the original article, there was a mistake in Figure 3 as published. On **Figure 3** panel F, an error was made when assembling the representative images on the board, and the same image was included twice for the SHR Control group and SHR Telm + PD group. The correct representative image for the SHR Control group was included and the corrected **Figure 3** appears below.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Copyright © 2021 Brito, Patrocínio, Linjardi, Barreto, Frasnelli, Lara, Santos and Oliveira. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.




FIGURE 3 | RAS components expression in mandibles of Wistar (non-hypertensive) and SHR with PD 15 days, treated with telmisartan. Respectively qRT-PCR and IHC for Agt (A,B), Ace (C,D), Agtr1 (E,F), and Agtr2 (G,H). Graphs show mean ± SEM (n = 6). Statistical difference are represented by brackets labeled by **p* < 0.05, ***p* < 0.01, ****p* < 0.001, and *****p* < 0.0001, comparing Control vs. PD, PD vs. Telm + PD, and Wistar vs. SHR in the same experimental condition. Board shows representative images, and upper table presents the average immunostaining pater from each experimental group (n = 5). Black arrows point bone forming cells positive stained (osteoblasts and osteocytes), and white arrows indicate positive stained alveolar bone adjacent connective tissue.